CMBA
CORT icon

C.M. Bidwell & Associates’s Corcept Therapeutics CORT Stock Holding History

C.M. Bidwell & Associates’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10
Closed -$325 – 493
2023
Q4 		$325 Sell
10
-4,596
-100% -$126K ﹤0.01% 468
2023
Q3 		$125K Buy
+4,606
New +$133K 0.1% 187
2020
Q3 		– Sell
-18,280
Closed -$307K – 467
2020
Q2 		$307K Buy
+18,280
New +$257K 0.28% 74
2020
Q1 		– Sell
-3,710
Closed -$45K – 375
2019
Q4 		$45K Buy
+3,710
New +$51.6K 0.04% 245

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

C.M. Bidwell & Associates's CORT Position: Q1 2024 in Review

C.M. Bidwell & Associates sold out of Corcept Therapeutics (CORT) in Q1 2024, closing a stake of 10 shares — an estimated $325 sold.

C.M. Bidwell & Associates first reported a position in CORT in Q4 2019 and held it in 4 quarters. The position peaked at $307K in Q2 2020. 287 funds tracked by Wall St. Rank hold CORT as of Q1 2024.

  • C.M. Bidwell & Associates reported no remaining Corcept Therapeutics position as of Q1 2024 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 10 Corcept Therapeutics shares in Q1 2024, an estimated $325.
  • C.M. Bidwell & Associates first reported a position in Corcept Therapeutics in Q4 2019 and held it in 4 quarters.
  • C.M. Bidwell & Associates's Corcept Therapeutics position peaked at $307K in Q2 2020.
  • 287 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2024.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2024, filed 14 May 2024.